Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4831 in Moderate to Severe COPD
2022-002441-18Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AZD4831 with Placebo (2 arms). Primary endpoint: Time to first COPDCompEx event. Started Sep 2022; status: completed.
02
Drugs
mitiperstat
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2022-002441-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002441-18.